{"id":"direct-acting-antiviral-therapy","brandName":"Direct-acting antiviral therapy","genericName":"Direct-acting antiviral therapy","companyId":"hospices-civils-de-lyon","companyName":"Hospices Civils de Lyon","phase":"phase_2","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Hospices Civils de Lyon is developing direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection, with ongoing trials in various populations including immunocompromised patients and transplant recipients. These DAAs aim to optimize antiviral treatment outcomes and expand therapeutic options.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Direct-acting antivirals work by directly inhibiting viral enzymes, thereby preventing viral replication. This class of drugs has been shown to be effective in treating various viral infections.","oneSentence":"Direct-acting antiviral therapy targets viral replication by inhibiting viral enzymes.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"30%","effect":"Headache"}]},"trials":[],"indications":{"approved":[{"name":"Hepatitis C"},{"name":"Hepatitis B"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}